{"id":15204,"date":"2012-08-15T00:30:00","date_gmt":"2012-08-14T22:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/merck-139-a-7466-mln-ebitda-ii-trim-alza-obiettivi-2012\/"},"modified":"2012-08-15T00:30:00","modified_gmt":"2012-08-14T22:30:00","slug":"merck-139-a-7466-mln-ebitda-ii-trim-alza-obiettivi-2012","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/merck-139-a-7466-mln-ebitda-ii-trim-alza-obiettivi-2012\/","title":{"rendered":"Merck: +13.9% to 746.6 mln ebitda II quarter, raises 2012 targets"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">(Il Sole 24 Ore Radiocor) \u2013 Darmstadt, August 14 \u2013 The German group Merck (chemicals, pharmaceuticals) closed the second quarter with an EBITDA net of extraordinary items up by 13.9% to 746.6 million, better than the 706 million forecast by analysts, but with a net loss of 60.5 million against -86.8 million a year earlier, more than the market forecast. The loss, the company specifies in a note, is due to charges of 376 million linked to the reorganization plan with savings of 300 million by 2014 announced in May for the pharmaceutical division. Turnover grew in the quarter by 11.6% to 2.85 billion. Sales of Rebif (multiple sclerosis) and Erbitux (antitumor), the best performing products, grew more than expected and the weakness of the euro supported overseas sales. Merck was optimistic for the rest of 2012 and raised its targets for the current year to 10.7 billion for turnover (10.5 billion previously) and to 2.85-2.95 billion for current ebitda (2.8-2.9 billion). Merck shares rose by 4.23% to 85.99 euros on the Frankfurt Stock Exchange.<\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span lang=\"EN-US\" style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-ansi-language: EN-US\">Red-mir-<\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span lang=\"EN-US\" style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-ansi-language: EN-US\">(RADIOCOR) 14-08-12 12:17:24 (0154) 5 NNNN&nbsp; <img","protected":false},"excerpt":{"rendered":"<p>(Il Sole 24 Ore Radiocor) &#8211; Darmstadt, 14 ago &#8211; Il gruppo tedesco Merck (chimica, farmaceutica) ha chiuso il secondo trimestre con un ebitda al netto di elementi straordinari in aumento del 13,9% a 746,6 milioni meglio dei 706 milioni previsti dagli analisti, ma con una perdita netta di 60,5 milioni contro -86,8 milioni un &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15204"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15204\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}